4.7
4.70 (-2.26%)
As of Mar 06, 2024
Sutro Biopharma, Inc. [STRO]
Source:
Company Overview
Sutro Biopharma, Inc. is a clinical-stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF®, and our site-specific conjugation platform, XpressCF ®. We aim to design and develop therapeutics using the most relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, or iADCs, dual conjugate ADCs, or ADC2s, and cytokine derivatives.
Country | United States |
Headquarters | south san francisco, california |
Phone Number | 650-392-8412 |
Industry | manufacturing |
CEO | William J. Newell |
Website | www.sutrobio.com |